ING Groep NV Has $4.64 Million Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

ING Groep NV trimmed its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,800 shares of the biotechnology company’s stock after selling 248,300 shares during the period. ING Groep NV owned 0.25% of Sarepta Therapeutics worth $4,640,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SRPT. AQR Capital Management LLC raised its holdings in Sarepta Therapeutics by 214.2% during the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the 1st quarter valued at about $224,000. Janney Montgomery Scott LLC raised its stake in shares of Sarepta Therapeutics by 123.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company’s stock valued at $492,000 after acquiring an additional 15,882 shares in the last quarter. IFP Advisors Inc lifted its holdings in Sarepta Therapeutics by 150.4% in the 2nd quarter. IFP Advisors Inc now owns 4,673 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 2,807 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in Sarepta Therapeutics by 542.3% in the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,771 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $17.40 on Friday. The firm’s 50-day moving average is $21.20 and its 200-day moving average is $20.10. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $111.21. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 2.95. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -5.78, a PEG ratio of 0.45 and a beta of 0.39.

Analysts Set New Price Targets

Several brokerages have commented on SRPT. Mizuho upgraded Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and increased their price target for the company from $19.00 to $26.00 in a report on Wednesday, November 5th. Wedbush raised their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a report on Tuesday, November 4th. Finally, HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Tuesday, January 27th. Nine analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Hold” and an average target price of $33.84.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the transaction, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.60% of the stock is owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.